单克隆抗体在哺乳期女性中的使用:不伤害还是获益有限?
许多神经系统疾病在女性育龄期高发,单克隆抗体(mAb)已成为偏头痛、多发性硬化、重症肌无力等的治疗选择,但围产期用药安全性研究匮乏。本文聚焦哺乳期mAb安全性,总结妊娠对疾病轨迹的影响及mAb治疗获益,提出神经科医生应主导现有mAb围产期安全性研究并建立未来研究框架。
要点
- 偏头痛、多发性硬化、重症肌无力等女性高发神经疾病中mAb应用渐广。
- 围产期(含哺乳期)处方药安全性研究严重不足,mAb亦然。
- 神经科医生应主导现有mAb的围产期安全性研究并建立研究框架。
核心结论
- 哺乳期mAb安全性证据匮乏,神经科医生应主导现有及未来mAb的围产期安全性研究。
研究设计与样本
- 本文为综述/观点性文章,聚焦哺乳期mAb安全性,总结妊娠对疾病轨迹的影响及mAb治疗获益,并提出研究框架。
主要发现
- 最新估计显示美国40-44岁女性中86%曾生育,但围产期处方药(含mAb)安全性研究仍匮乏。
- 偏头痛、多发性硬化、重症肌无力等神经疾病在女性育龄期高发,mAb治疗应用日益广泛。
临床怎么用
- 神经科医生应关注哺乳期mAb使用的安全性证据缺口,并推动现有mAb的围产期安全性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many neurologic diseases disproportionately affect women, particularly during their reproductive years. For many of these diseases, monoclonal antibodies (mAbs) are becoming widely available as a treatment option, for example, in migraine, multiple sclerosis, and myasthenia gravis. Yet, despite how common pregnancy is (latest estimates suggest that 86% of US women ages 40-44 have given birth), there is a paucity of research on the safety of prescription medications, including mAbs, during the peripartum period. In this article, we focus on the safety of mAbs during breastfeeding. We summarize how pregnancy affects the trajectory of these diseases and explore the benefit derived from mAb therapies. We posit that as neurologists, we are uniquely poised to lead the study of peripartum safety for the mAbs now on the market and provide a framework for their future study.
引用
- LaHue SC, Gelfand AA, Bove RM, et al. Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good? Neurology. 2019. PMID: 31492717. doi:10.1212/WNL.0000000000008213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。